InvestingPro’s fair value spotted Insmed’s 47% drop 10 months early

In December 2025, NASDAQ-listed Insmed Incorporated (INSM) was trading at $189.80 per share. InvestingPro's Fair Value models flagged the biotech stock as significantly overvalued, anticipating a 47% decline to $100.60 by October 2026. This case study showcases how Fair Value analysis helps investors spot mispriced securities by calculating a stock's intrinsic worth through multiple valuation methods.

Despite Insmed generating $447 million in revenue, operating at a loss with an EBITDA of -$979 million and EPS of -$6.22, the stock had surged 44% in June 2025 and 32% in October 2025. InvestingPro's Fair Value analysis determined an intrinsic price of $111.64, indicating a 41% downside from the $189.80 market price. The actual price decline validated the analysis.

While Insmed improved operationally with revenue increasing to $1.14 billion and losses narrowing, the disconnect between business performance and valuation multiples emphasizes the importance of valuation in determining stock returns. Insmed's recent progress, including strong BRINSUPRI and ARIKAYCE launches, earned positive analyst coverage, yet clinical setbacks led to volatility.

Currently trading at $100.60, the stock is closer to its fair value estimate of $88.41, illustrating how Fair Value analysis provides continuous guidance as circumstances change.